Kaléo Inc. said on Wednesday that it will relaunch its Auvi-Q injector for emergency allergy treatment in the 1st half of 2017 in the U.S., according to Reuters.
The Richmond, Virginia-based company’s device was recalled last year after concerns about the accuracy of delivered dose. Sanofi (NYSE:SNY) made and licensed the Auvi-Q device from Kaléo, but returned rights to the product in February following the recall.
Get the full story at our sister site, Drug Delivery Business News.
The post Kaléo plans 2017 U.S. relaunch for EpiPen comptetitor Auvi-Q appeared first on MassDevice.
from MassDevice http://ift.tt/2dL4yW5
Cap comentari:
Publica un comentari a l'entrada